A Pittsburgh startup is potentially exploiting survivors by selling unproven kits to gather evidence of sexual assault, according to an opinion article published Monday in the peer-reviewed journal JAMA Internal Medicine.

The article adds a medical perspective to a growing list of opposition against Leda Health, a startup the Post-Gazette first reported on in February.

“While possibly well intentioned, these at-home SAKs are unregulated by the U.S. Food and Drug Administration [FDA] and currently lack clinical and legal legitimacy,” researchers from Harvard Medical School and the Yale School of Medicine wrote.

The kits “warrant intervention from policymakers because they currently do not meet standards for clinical utility and, worse, risk disadvantaging survivors of their ability to seek judicial recourse.”

Advertise with us

The article, titled “At-Home Testing for Survivors of Sexual Assault — Empowerment or Exploitation?” directly cites reporting by the Post-Gazette that found Leda Health was garnering military contracts and selling its kits to sororities without evidence that they could be used in trial.

Leda is currently suing officials in Pennsylvania, New York and Washington state and seeking an injunction to allow it to continue selling the controversial kits, which experts say can’t be used to prosecute sexual assault and therefore give survivors false hope.

A hearing on the injunction is scheduled for Aug. 26 in federal court in Pittsburgh. Leda CEO Madison Campbell plans to testify. The startup has said that banning the sale of the kits violates First Amendment rights.

Pennsylvania’s attorney general sued Leda Health in June, alleging that the kits violate Pennsylvania’s consumer protection law, fail to meet evidence collection standards and mislead consumers.

In the JAMA piece, researchers argued that the FDA has oversight over such kits and should therefore request evidence of their “clinical and analytic validity.”

Advertise with us

“Absent voluntary disclosure, the FDA could investigate whether these products’ advertising claims constitute misbranding under the Federal Food, Drug, and Cosmetic Act warranting regulatory action,” the article states. “The FDA could also issue guidance to patients and clinicians about the clinical utility and limitations of these products, which in turn could inform ongoing state-level efforts at regulation.”

The researchers recognize, however, that there are significant problems with the current testing landscape for sexual assault that the kits attempt to solve.

“While at-home SAKs in their current iteration are not the solution, their deficiencies should not distract from the challenges that motivated their creation,” the article states. “Barriers to care and inefficiencies in criminal justice for sexual assault require further policy action.”

They suggest building a national database of Sexual Assault Nurse Examiner programs, as Congress requested in 2022, and funding programs to end the multistate backlog of unprocessed forensic kits.

Leda Health, through its lawyer, pushed back against the article and the assertion that the FDA has oversight.

Advertise with us

“It’s doctors talking about the law,” said attorney Alex Little. “Unfortunately, this op-ed, like other opinion pieces, sort of misunderstands the applicable regulatory regime and what it is that Leda does.”

“The whole idea is that this agency needs to regulate this stuff, which isn't under its jurisdiction,” he said, arguing that it was akin to suggesting “the FDA should regulate airplanes.”

The FDA did not immediately respond to a request for comment.